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Rationale: There are no accepted blood-based biomarkers in chronic
obstructive pulmonary disease (COPD). Pulmonary and activation-
regulated chemokine (PARC/CCL-18) is a lung-predominant inflam-
matory protein that is found in serum.
Objectives: To determine whether PARC/CCL-18 levels are elevated
and modifiable in COPD and to determine their relationship to
clinical end points of hospitalization and mortality.
Methods: PARC/CCL-18 was measured in serum samples from in-
dividuals who participated in the ECLIPSE (Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints) and LHS
(Lung Health Study) studies and a prednisolone intervention study.
Measurements and Main Results: Serum PARC/CCL-18 levels were
higher in subjectswithCOPDthan in smokersor lifetimenonsmokers
without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P , 0.0001).
Elevated PARC/CCL-18 levels were associated with increased risk of
cardiovascular hospitalization or mortality in the LHS cohort and
with total mortality in the ECLIPSE cohort.
Conclusions: Serum PARC/CCL-18 levels are elevated in COPD and
track clinical outcomes. PARC/CCL-18, a lung-predominant chemo-
kine, could be a useful blood biomarker in COPD.
Clinical trial registeredwithwww.clinicaltrials.gov (NCT00292552).
Keywords: biomarker; chronic obstructive pulmonary disease; PARC/
CCL-18; chemokine
Chronic obstructive pulmonary disease (COPD) is a major
health burden worldwide, affecting 10 to 15% of the adult
population 40 years and older (1) and responsible for 3 million
deaths annually (2). Although there has been rapid expansion in
our understanding of COPD pathogenesis, therapeutic options
remain limited. One major barrier to drug discovery has been
the lack of reliable, robust, reproducible, and modifiable bio-
markers that can act as intermediate surrogate end points for
clinical studies (3). Although biomarkers can be obtained from
any organ, the most attractive is blood because it is readily
accessible and its measurements can be easily standardized.
However, because most serum proteins are secreted by non-
pulmonary organs such as the liver and the bone marrow, their
use may be limited in COPD. This problem is largely avoided
for proteins secreted predominantly by the lungs (i.e., pneumopro-
teins). PARC (pulmonary and activation-regulated chemokine)/
CCL-18 (CC-chemokine ligand-18) is a 7-kD protein that is
constitutively expressed by monocytes/macrophages and den-
dritic cells and is secreted predominantly in the lungs (4).
Although the exact biological role of PARC/CCL-18 is not
known, serum levels are elevated in acute coronary syndromes
(5), with idiopathic pulmonary fibrosis (6), and in childhood
acute lymphoblastic leukemia (7). Interestingly, in idiopathic
pulmonary fibrosis, serum PARC/CCL-18 levels may reflect
fibrotic activity and correlate with survival (8). Pertinent to
COPD, in one small study of patients with mild to moderate
disease, serum PARC/CCL-18 levels were significantly associ-
ated with reduced FEV1 and with the BODE (body mass index,
airflow obstruction, dyspnea, and exercise capacity) Index score
(9), whereas in another, circulating PARC/CCL-18 levels were
found to associate with acute exacerbations (10). Although
these data are promising, several critical questions remain
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Scientific Knowledge on the Subject
Chronic obstructive pulmonary disease (COPD) is an
independent risk factor for poor cardiovascular (CVD)
health outcomes. However, there are no good blood-based
biomarkers that can be used to predict these end points.
What This Study Adds to the Field
The present study shows that PARC (pulmonary and
activation-regulated chemokine)/CCL-18 (CC-chemokine
ligand-18) associates with cardiovascular hospitalizations
and mortality.
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unanswered regarding the possible use of PARC/CCL-18 as
a biomarker in COPD, including its relationship with clinical
outcomes such as hospitalization and mortality and its respon-
siveness to pharmacologic therapy. Using two large COPD
cohorts, we determined the relationship of serum PARC/
CCL-18 levels with lung function and mortality and determined
whether PARC/CCL-18 levels can be down-regulated by pred-
nisolone as a proof-of-concept that they can be modulated by an
antiinflammatory drug. Some of the data have been published
previously in abstract form (11).
METHODS
See the online supplement for the details on methods.
Subjects and Cohorts
For this study, we used data from three COPD cohorts: (1) the Lung
Health Study (LHS, NCT00000568), (2) Evaluation of COPD Longi-
tudinally to Identify Predictive Surrogate Endpoints (ECLIPSE), and
(3) a prednisolone intervention study. The details of these cohorts have
been previously published (12–14) and can be found in the online
supplement. LHS enrolled smokers between the ages of 35 to 60 years
who had mild to moderate airflow obstruction as defined by an FEV1 of
less than 90% but at least 55% of predicted, in the presence of an
FEV1/FVC ratio less than 0.70. At the fifth annual visit, venipuncture
was performed on 4,825 LHS participants, representing 89% of sub-
jects known to be alive at Year 5. During the follow-up, the
participants’ vital status was captured semiannually. Vital status was
successfully determined for 98.3% of the participants (15). On the basis
of adjudication by an expert panel, mortality end points in LHS were
classified as follows: malignancies; respiratory failure; coronary heart
disease (CHD); and cardiovascular disease (CVD), which included
CHD as well as other CVDs such as stroke (15).
ECLIPSE
ECLIPSE (NCT00292552, GlaxoSmithKline study no. SCO104960) is
a 3-year multicenter longitudinal observational study to identify novel
end points in COPD. Individuals aged 40–75 years were recruited to the
study if they had a smoking history of at least 10 pack-years; a post-
bronchodilator FEV1/FVC ratio not exceeding 0.7; and GOLD (Global
Initiative for Obstructive Lung Disease) stage II (FEV1, 50–80%
predicted), III (30% < FEV1, ,50% predicted), or IV (FEV1 , 30%
predicted) COPD (16). Smoking (>10 pack-years) and nonsmoking (,1
pack-year) control subjects were enrolled if they had normal lung func-
tion (postbronchodilator FEV1 . 85% predicted and FEV1/FVC . 0.7).
Prednisolone Intervention Study
For the prednisolone intervention study (NCT00379730, GlaxoSmith-
Kline study no. RES106087), 89 current and former smokers were
recruited, aged 40 to 80 years, with postsalbutamol FEV1 between 30
and 80% of predicted and with chronic bronchitis. Individual subjects
were randomized to receive either placebo or prednisolone (20 mg/d)
for 4 weeks followed by prednisolone at 10 mg/day for 1 week, and
prednisolone at 5 mg/day for 1 week. All subjects were followed up 2
weeks after the end of treatment.
Measurements
LHS was used as the derivation cohort and ECLIPSE was used as the
replication cohort. In LHS samples, we measured PARC/CCL-18 and
26 other serum proteins, using a highly sensitive chemiluminescence
multiplexed sandwich ELISA analyzer (SearchLight proteome array
system; Pierce Biotechnology Inc, Rockford, IL) (13) (see the online
supplement for the list of serum proteins). In the ECLIPSE study
serum samples, PARC/CCL-18 levels were measured with a human
CCL18/PARC DuoSet ELISA kit (R&D Systems, Minneapolis, MN).
The prednisolone study was used as an interventional cohort and the
study samples were assayed for PARC/CCL-18, using the same
platform as for the LHS samples.
Statistical Analysis
To determine the relationship of serum PARC/CCL-18 concentrations
with total and cause-specific mortality and hospitalization in LHS, we
used a Cox regression analysis in which serum PARC/CCL-18 levels
were divided into five equal-sized groups. Covariates that were
considered in this model included age, sex, body mass index (BMI),
smoking status through the first 5 years of follow-up, O’Connor slope
for bronchial responsiveness (17), pack-years of smoking, blood
pressure at Year 5, and FEV1 (percent predicted) at Year 5. Only
the covariates that were significant according to the LASSO (least
absolute shrinkage and selection operator) method were included in
the final model (see Table 3). The same covariates were used in the
replication study using ECLIPSE.
RESULTS
Serum PARC/CCL-18 in LHS
The baseline characteristics of subjects at the time of blood
collection for both LHS and ECLIPSE are summarized in Table
1. In the LHS, there were 329 deaths (6.8% of the LHS subjects
in whom PARC/CCL-18 levels were determined). Of the LHS
TABLE 1. BASELINE CHARACTERISTICS OF LHS AND ECLIPSE COHORT
ECLIPSE
Lung Health Study Subjects with COPD Smoker Control Subjects Nonsmoker Control Subjects
Number of subjects 4,825 1,809 312 226
Age, yr 54 (7) 63 (7) 55 (9) 54 (9)
Men 3,036 (63%) 1,175 (65%) 172 (55%) 87 (39%)
White 4,644 (96%) 1,772 (98%) 305 (98%) 222 (98%)
Pack-years of smoking 40 (19) 48 (27) 32 (22) 0
BMI, kg/m2 26 (4) 27 (6) 27 (5) 28 (5)
FEV1, L 2.54 (0.67) 1.36 (0.52) 3.34 (0.76) 3.31 (0.80)
FEV1, % predicted 71.0 (12.4) 49 (16) 109 (12) 115 (14)
Intermittent smokers 1363 (28%) N/A N/A 0
Continuing smokers 855 (18%) 644 (36%) 192 (62%) 0
Chronic sputum* 1,477 (31%) 899 (50%) 54 (17%) 9 (4%)
Chronic cough* 1,697 (35%) 866 (48%) 60 (19%) 12 (5%)
PARC/CCL-18, ng/ml† 97 (34) 105 (26) 81 (21) 80 (18)
Definition of abbreviations: BMI 5 body mass index; COPD 5 chronic obstructive pulmonary disease; ECLIPSE 5 Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints; LHS 5 Lung Health Study; N/A 5 not available; PARC/CCL-18 5 pulmonary and activation-regulated chemokine/CC-chemokine
ligand-18.
Continuous data are expressed as means (SD) and dichotomous variables are expressed as number (percentage of column totals). Serum PARC/CCL-18
concentrations are expressed as medians (median absolute deviation).
* At baseline.
† Median (median absolute deviation).
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subjects in whom PARC/CCL-18 levels were determined, 51
died (1.1%) of CHD, and 87 died of CVD (1.8%). In addition,
508 patients (10.5%) experienced a CHD hospitalization or
CHD death and 820 (17.2%) experienced a CVD hospitaliza-
tion or CVD mortality. In the LHS, PARC/CCL-18 was related
to the risk of CVD hospitalization or mortality (adjusted hazard
ratio [HR], 1.28; 95% confidence interval [CI], 1.13 to 1.45) and
CHD hospitalization or mortality (adjusted HR, 1.33; 95% CI,
1.14 to 1.56). PARC/CCL-18 levels were not related to total
mortality (Tables 2 and 3). PARC/CCL-18 was related to the
patients’ baseline FEV1 percent predicted value (for every 10%
predicted increase in FEV1, PARC/CCL-18 decreased by 3.0%;
P , 0.0001; see Figure E1 in the online supplement). PARC/
CCL-18 levels were also related to patients’ age (a 10-yr increase
was associated with an 8.7% increase in PARC/CCL-18 levels),
to BMI (a 1-kg/m2 increase was associated with a 1.9% increase
in PARC/CCL-18 levels), to sex (men had 10% greater PARC/
CCL-18 levels than women), and to smoking status (all with P ,
0.0001). For the latter, continuing smokers had the lowest PARC/
CCL-18 levels, whereas sustained quitters had the highest.
Continuing smokers had PARC/CCL-18 levels that were on
average 6% lower than those of sustained quitters (P 5 0.005).
Serum PARC/CCL-18 in ECLIPSE and Prednisolone
Intervention Study
At study entry in ECLIPSE, serum PARC/CCL-18 levels were
measured in 1,809 subjects with COPD, 312 smoking control
subjects without airflow obstruction, and 226 nonsmoking
control subjects. Median concentrations of serum PARC/
CCL-18 were higher in the subjects with COPD compared with
both control groups (105 ng/ml vs. 81 and 80 ng/ml in subjects
with COPD, smoking control subjects, and nonsmoking control
subjects, respectively; P , 0.001) (Figure 1). However, there
were no significant differences in serum PARC/CCL-18 con-
centrations across the GOLD stages. As in the LHS, the median
serum PARC/CCL-18 concentrations were higher in former
than in current smokers both within subjects with COPD (111
vs. 96 ng/ml; P , 0.001) and within smoker control subjects (89
vs. 75 ng/ml; P 5 0.01) (Figure E2). Similar observations were
also noted in subjects with COPD when separated according
to GOLD stages. Within a GOLD stage, the median PARC/
CCL-18 concentrations were generally higher in former
smokers than in current smokers (GOLD II: 111 vs. 97 ng/ml,
P , 0.001; GOLD III: 112 vs. 95 ng/ml, P , 0.001; GOLD IV:
106 vs. 100 ng/ml, P 5 0.12). As in LHS, men had higher serum
PARC/CCL-18 concentrations than women (COPD cohort,
108 vs. 100 ng/ml; P, 0.001) and PARC/CCL-18 was associated
with age (a 10-yr increase was associated with a 9% increase in
PARC/CCL-18 levels) and BMI (a 1-kg/m2 increase was
associated with a 1.3% increase in PARC/CCL-18 levels). Of
the 1,809 subjects with COPD with PARC/CCL-18 levels
measured, 151 died (all causes) during the 3-year observation
time (39, 76, and 36 subjects in GOLD stage II, III, and IV,
respectively). The median serum PARC/CCL-18 concentrations
in those who died was higher than in the 1,659 subjects with COPD
alive at 3 years (122 vs. 104 ng/ml; P 5 0.003). Figure 2 depicts
a Kaplan-Meier survival curve of subjects whose serum PARC/
CCL-18 levels were above and less than or equal to 147 ng/ml,
which represents the 95th percentile of nonsmoking control
subjects (Figure 2). Adjusting for age, sex, BMI, and smoking
status, the hazard ratio for PARC/CCL-18 levels above 147 ng/
ml was 1.90 (95% CI: 1.34, 2.69; P , 0.001). Importantly, in the
ECLIPSE samples, the serum PARC/CCL-18 concentrations
were stable over 1 year (data not shown). In the prednisolone
interventional study, treatment with prednisolone resulted in
a significant reduction in serum PARC/CCL-18 levels from 137
TABLE 2. RELATIONSHIP BETWEEN SERUM PARC/CCL-18 CONCENTRATIONS AND TOTAL MORTALITY, CORONARY HEART DISEASE,
AND CARDIOVASCULAR HOSPITALIZATION AND MORTALITY IN THE LUNG HEALTH STUDY
End Point
PARC/CCL-18 as Continuous
Variable (log scale)
PARC/CCL-18 (quintiles)
Q2 Q3 Q4 Q5 (highest) P Value for Trend
Total mortality 1.14 (0.93, 1.38) 1.16 (0.80, 1.70) 1.15 (0.80, 1.67) 1.24 (0.86, 1.79) 1.25 (0.87, 1.80) 0.27
Coronary heart disease deaths 1.26 (0.76, 2.08) 1.04 (0.32, 3.42) 2.44 (0.89, 6.72) 1.48 (0.50, 4.38) 1.52 (0.52, 4.43) 0.45
Cardiovascular deaths 1.20 (0.82, 1.77) 0.77 (0.34, 1.74) 1.10 (0.53, 2.30) 1.18 (0.57, 2.44) 1.05 (0.51, 2.17) 0.54
CHD hospitalization and deaths 1.33 (1.14, 1.56) 1.28 (0.90, 1.82) 1.63 (1.17, 2.26) 1.74 (1.25, 2.41) 1.83 (1.33, 2.53) ,0.01
CVD hospitalization and deaths 1.28 (1.13, 1.45) 1.15 (0.89, 1.49) 1.22 (0.95, 1.56) 1.53 (1.20, 1.94) 1.51 (1.19, 1.91) ,0.01
Definition of abbreviations: CHD 5 coronary heart disease; CVD 5 cardiovascular disease (which also includes CHD); PARC/CCL-18 5 pulmonary and activation-
regulated chemokine/CC-chemokine ligand-18; Q 5 quintile.
Each cell expresses an adjusted hazards ratio (95% confidence interval) using quintile 1 as the referent, adjusted for covariates selected by LASSO (least absolute
shrinkage and selection operator) from age, sex, FEV1 (percentage of predicted normal values), current smoking status, pack-years of smoking, body mass index, and
other covariates (see METHODS).
TABLE 3. CLINICAL VARIABLES ASSOCIATED WITH SERUM PARC/CCL-18 CONCENTRATIONS IN LHS AND ECLIPSE PATIENTS
WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LHS ECLIPSE COPD
Change in Variable* Relative Ratio (95% CI) P Value Relative Ratio (95% CI) P Value
10-yr increase in age 1.09 (1.06, 1.12) ,0.001 1.09 (1.07, 1.12) ,0.001
Males vs. females 1.10 (1.06,1.14) ,0.001 1.05 (1.02, 1.09) 0.004
10–pack-year smoking increase 1.01 (1.00, 1.02) 0.068 1.00 (0.99, 1.01) 0.984
One unit change in BMI, kg/m2 1.02 (1.01, 1.02) ,0.001 1.01 (1.01, 1.02) ,0.001
FEV1 increase of 10% predicted 0.97 (0.96, 0.98) ,0.001 1.00 (0.99, 1.01) 0.737
Continuing smokers vs. quitters† 0.95 (0.90, 0.99) 0.016 0.93 (0.90, 0.96) ,0.001
Definition of abbreviations: BMI 5 body mass index; COPD 5 chronic obstructive pulmonary disease; ECLIPSE 5 Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints; LHS 5 Lung Health Study; PARC/CCL-18 5 pulmonary and activation-regulated chemokine/CC-chemokine ligand-18.
* Change in individual variables holding other covariates fixed at their mean value.
† For ECLIPSE, this compares current smokers versus former smokers.
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to 98 ng/ml at 2 weeks (P , 0.001 vs. placebo; see Figure E3).
See the online supplement for additional results.
DISCUSSION
Using two large COPD cohorts and an intervention study,
PARC/CCL-18 appears to be a promising blood biomarker in
COPD by fulfilling some of the important criteria of a bio-
marker, including its independent association with lung func-
tion, morbidity and mortality, and responsiveness to therapy
(18). First, in the ECLIPSE study, we found that serum PARC/
CCL-18 concentrations were independently related to COPD;
whereas in the LHS, a large cohort of smokers with mild to
moderate COPD (GOLD stages I and II), we found a significant
relationship with lung function, as measured by FEV1 percent
predicted. Second, we observed a strong, independent relation-
ship of PARC/CCL-18 concentrations with future risk of
cardiovascular hospitalization and mortality (in the LHS) and
with total mortality (in ECLIPSE). Third, in the prednisolone
interventional study, we found that serum PARC/CCL-18 levels
could be modified by the short-term use of prednisolone, similar
to what has been previously reported (19), which suggests that
PARC/CCL-18 may be modifiable by systemic antiinflamma-
tory therapy. Together, these data suggest that PARC/CCL-18
may be a useful candidate blood biomarker in COPD.
PARC/CCL-18 is an z7-kD protein, which is expressed
mainly by dendritic cells (20) and alternatively activated (M2)
macrophages in the lungs (21) in response to helper T-cell type
2 cytokines. Minor expression has been noted in other in-
flammatory cells including peripheral mononuclear cells and
neutrophils (22). Its precise function is not fully known.
However, PARC/CCL-18 has been demonstrated to preferen-
tially attract naive T cells to areas of injury, amplifying the
initial inflammatory response (23). It can also stimulate lung
fibroblasts to produce collagen by up-regulating the extracellu-
lar signal–regulated kinase-1/2 pathway (24). Serum concentra-
tions of PARC/CCL-18 are elevated in patients with pulmonary
fibrosis, which in turn correlate with increased fibrotic activity in
the lungs and with reduced overall survival of these patients (8).
There is a paucity of data evaluating the role of PARC/CCL-
18 in COPD. In a cross-sectional study, Pinto-Plata and
colleagues showed that serum PARC/CCL-18 levels correlated
significantly with reduced FEV1 percent predicted values, in-
creased the risk of exacerbation, and increased BODE Index,
indicating poor prognosis (9). In another study, Hurst and
colleagues demonstrated that during exacerbations, plasma
PARC/CCL-18 levels increased by 10% compared with those
during clinical stability (10), suggesting that this cytokine may
be up-regulated during disease flare-ups and may be used as
a biomarker of exacerbations. However, it should also be noted
that although PARC/CCL-18 expression occurs mostly in the
lungs, other organs including the prostate, bone marrow, blood
vessels, and the liver also express this protein. Interestingly,
serum PARC/CCL-18 levels rise during ischemic myocardial
events and these levels predict future risk of cardiovascular
morbidity and mortality (5). This latter observation may explain
Non-Smoker Smoker COPD GOLD II GOLD III GOLD IV
0
50
100
150
200
250
300
Controls Controls Cohort n=822 n=752 n=235
n=226 n=312 n=1809
Figure 1. The relationship between serum PARC (pulmonary and
activation-regulated chemokine)/CCL-18 (CC-chemokine ligand-18)
concentrations and chronic obstructive pulmonary disease (COPD) in
the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints) study. (P , 0.001 between COPD and control
subjects; no difference between GOLD [Global Initiative for Obstructive
Lung Disease] stages.)
Figure 2. Kaplan-Meier survival curves of ECLIPSE
(Evaluation of COPD Longitudinally to Identify Pre-
dictive Surrogate Endpoints) patients with chronic
obstructive pulmonary disease (COPD) stratified by
serum PARC (pulmonary and activation-regulated
chemokine)/CCL-18 (CC-chemokine ligand-18) con-
centrations (147 ng/ml represents 95th percentile
of control subjects).
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why in the LHS we observed a significant relationship between
serum PARC/CCL-18 concentrations and the risk of cardiovas-
cular hospitalization and mortality. Additional work will be
needed to validate this early finding.
Although the LHS and the ECLIPSE study were conducted
in different populations, across different time periods and with
a different set of goals and objectives, there was remarkable
consistency and complementarity of PARC/CCL-18 findings
between the two studies. In both studies, serum PARC/CCL-18
concentrations were significantly related to increasing age, male
sex, BMI, and smoking status. Interestingly, in both studies, ex-
smokers had higher serum expression than did current smokers.
Moreover, in both studies, total smoking exposure (as measured
by pack-years of smoking) was not significantly associated with
serum PARC/CCL-18 concentrations, indicating the impor-
tance of current smoking (or nonsmoking) status in modulating
this protein. These clinical data are consistent with those of
Kollert and colleagues, who showed that smoking attenuates
PARC/CCL-18 expression by alveolar macrophages (25).
However, there were some notable discordances between
the findings in the LHS and those in ECLIPSE. First, in the
LHS but not in ECLIPSE, serum PARC/CCL-18 levels were
associated with FEV1 percent predicted. One possible reason is
that the LHS had almost twice the sample size of ECLIPSE,
which may have provided sufficient statistical power to detect
this relationship. Another possibility is that the LHS studied
predominantly patients with mild to moderate COPD whereas,
in ECLIPSE, there was nearly equal representation of patients
in GOLD class II and III and also a large representation of
patients from GOLD class IV. It may be that the relationship of
PARC/CCL-18 is (inversely) linear in earlier disease severity
but nonlinear in later stages. The discordance in the FEV1 data
also raises the possibility that the relationship between FEV1
and serum PARC/CCL-18 levels observed in the LHS could
have been spurious. Additional work in other cohorts will be
needed to determine which of these hypotheses, if any, are
valid. Third, in LHS, total mortality was not associated with
serum PARC/CCL-18 concentrations, whereas in ECLIPSE, it
was significantly related. Fewer than 7% of the LHS partici-
pants died during an average follow-up of 8 years (resulting in
an annual mortality rate of less than 1%). Thus, we may have
lacked sufficient statistical power to assess mortality in the LHS.
In contrast, by sampling patients with greater disease severity,
patients in ECLIPSE had a higher mortality rate than those in
the LHS, with nearly 10% mortality over 3 years of follow-up
(resulting in an annual mortality rate of approximately 3%),
resulting in more robust statistical power for this end point.
There were some limitations to the present study. Because
only one additional lung function measurement was obtained
after blood collection in the LHS, we could not determine the
relationship of serum PARC/CCL-18 levels to the rate of
descent in FEV1. Second, there were insufficient numbers of
cardiovascular hospitalizations in ECLIPSE to determine the
relationship of this protein with cardiovascular events and in the
LHS, we did not have information about significant prognostic
variables such as the BODE Index. As such, the value of serum
PARC/CCL-18 above and beyond the BODE Index and other
composite scores in predicting health outcomes in COPD is
uncertain. In ECLIPSE, there was only a loose relationship
between BODE Index scores and PARC/CCL-18 levels. Third,
blood samples for the LHS have been stored at 2808C for more
than a decade. Although the blood samples have been well
preserved and not subjected to repeat freeze–thaw cycles, the
effect of long-term storage on most serum proteins is uncertain.
Nevertheless, it was reassuring that the serum PARC/CCL-18
levels in the LHS subjects were similar to those in the ECLIPSE
subjects. Fourth, in the LHS, we measured multiple proteins (27
in total) and we cannot discount the possibility that the positive
associations of serum PARC/CCL-18 to clinical end points in
this cohort may have been spurious, owing to multiple compar-
isons. However, replication of some (but not all) of the findings
of the LHS in ECLIPSE was reassuring. Last, it should be noted
that serum PARC/CCL-18 measurements have not been stan-
dardized and as such absolute levels may not be comparable
across studies. Thus, the data are best interpreted in relative
(rather than absolute) terms.
In summary, these large COPD cohorts demonstrate PARC/
CCL-18 as a promising serum biomarker in COPD. It is up-
regulated in COPD and independently associated with impor-
tant health outcomes such as total mortality and cardiovascular
morbidity and mortality. Additional work needs to be done to
validate these findings in other cohorts and, most importantly,
to determine whether or not this protein is in the causal
pathway of disease pathogenesis.
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